Fig. 6.

JK184 combined with ICB synergistically induces tumor regression. BALB/c mice were subcutaneously inoculated with 4T1 tumor cells, and C57BL/6 mice were subcutaneously inoculated with MC38 tumor cells. The above mice were sacrificed, and tumors were removed and photographed at the treatment endpoint. A Timeline of mouse models of 4T1 tumor cells with treatment schedules. B 4T1 tumor growth in the control group, PD1 group, JK184 group and PD1 plus JK184 treatment group (n = 6 mice per group). C Kaplan–Meier curves showing the overall survival of 4T1 tumor-bearing mice treated with either control, PD1, JK184, or PD1+JK184. D Diagram depicting the treatment schedule for the MC38 tumor model. In our models, JK184 was combined with PD1 or CTLA antibody for treatment. E and F MC38 tumor growth resulting from tumors treated with control, PD1 (CTLA4), JK184, or PD1 (CTLA4)+JK184. G and H Percent survival was analyzed using Kaplan–Meier analysis in the two models. I and J Representative tumor pictures are shown. T tests were used to determine statistical significance of the differences in B, E and F. **P < 0.01, ***P < 0.001 and ****P < 0.0001, ns not significant. P values for C, G and H were determined by the log-rank test, two-tailed, *P < 0.05, **P < 0.01, ****P < 0.0001, ns not significant